Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
By
Joseph Haas / Email the Author / “The Pink Sheet” Jan. 9, 2012, Vol. 74, No. 2
Business & Finance / Word Count: 2007 / Article # 00120109025
Executive Summary
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.